Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Investigational New Drugs
Motohiro TamiyaDaichi Fujimoto

Abstract

Objectives As first line therapy, pembrolizumab provides longer progression free survival (PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) with tumor propensity scores (TPS) ≥50%. However, clinical trials do not represent real-world patients. Materials and Methods This multicenter retrospective study conducted across 11 medical centers in Japan analyzed clinical data from patients receiving first-line pembrolizumab for NSCLC between February 1, 2017 and April 30, 2018. The efficacy, safety, and suitability of pembrolizumab monotherapy were evaluated. Results The median age of the 213 enrolled patients was 71 (range: 39-91) years. Among them, 176 (82.6%) were male, 20 (9.4%) were never smokers (median Brinkman index: 900), 172 (80.8%) had an ECOG PS of 0-1, 55 (25.8%) had squamous-cell carcinoma (SQ). PD-L1 TPS were 50-74%, 75-89%, and 90-100% in 97 (45.5%), 47 (22.1%), and 69 (32.4%) patients, respectively. Adverse events (AEs) of grades ≥3 were observed in 39 (18.3%) patients. Pneumonitis was the most common severe AE, occurring in 10 patients (4.7%) including 1 with grade 4 toxicity; no severe AE-related deaths occurred. The overall respons...Continue Reading

References

Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Stephen G Spiro, Joanna C Porter
Mar 18, 2005·Annual Review of Immunology·Rebecca J GreenwaldArlene H Sharpe
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey LangerUNKNOWN Eastern Cooperative Oncology Group
Jul 20, 2010·Immunological Reviews·Loise M FranciscoArlene H Sharpe
Dec 15, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Maria Q BaggstromRamaswamy Govindan
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Feb 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara MeloskyVera Hirsh
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 17, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Daichi FujimotoToyohiro Hirai
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Aug 21, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn C ArbourMatthew D Hellmann
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Jan 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckJulie R Brahmer

❮ Previous
Next ❯

Citations

Mar 2, 2021·Therapeutic Advances in Medical Oncology·Jingjing QuJianying Zhou
Mar 30, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Francesco FacchinettiMarcello Tiseo
Jun 19, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Bartłomiej TomasikRafał Dziadziuszko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.